Trial · NCT05208866
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Number of Participants Who Develop Serum ALT Levels >3 × ULN During the Lixivaptan Re-titration or Maintenance Treatment Periods Assessed to be Related to Lixivaptan and Resulted in Discontinuation of Lixivaptan Treatment | All Enrolled Participants | 0 | Participants | ||
Number of Participants Who Develop Serum ALT Levels >5 x ULN During the Lixivaptan Re-titration or Maintenance Treatment Periods Assessed to be Related to Lixivaptan and Resulted in Discontinuation of Lixivaptan Treatment | All Enrolled Participants | 0 | Participants | ||
Number of Participants Who Develop Serum ALT Values >3 × ULN During the Lixivaptan Re-titration or Maintenance Treatment Periods Assessed to be Related to Lixivaptan and Resulted in Dose Reduction of Lixivaptan Treatment | All Enrolled Participants | 0 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All Enrolled Participants | Lixivaptan Re-titration and Maintenance Treatment Periods | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | All Enrolled Participants | Follow-up Period | 0 | Participants | |
| Number of Participants With Potentially Clinically Important Clinical Laboratory Findings | All Enrolled Participants | Lixivaptan Re-titration and Maintenance Treatment Periods | 0 | Participants | |
| Number of Participants With Potentially Clinically Important Clinical Laboratory Findings | All Enrolled Participants | Follow-up Period | 0 | Participants | |
| Number of Participants With Potentially Clinically Important Vital Signs Findings | All Enrolled Participants | Lixivaptan Re-titration and Maintenance Treatment Periods | 0 | Participants | |
| Number of Participants With Potentially Clinically Important Vital Signs Findings | All Enrolled Participants | Follow-up Period | 0 | Participants | |
| Number of Participants With Potentially Clinically Important 12-lead Electrocardiogram (ECG) Findings | All Enrolled Participants | Lixivaptan Re-titration and Maintenance Treatment Periods | 0 | Participants | |
| Number of Participants With Potentially Clinically Important 12-lead Electrocardiogram (ECG) Findings | All Enrolled Participants | Follow-up Period | 0 | Participants | |
| Annualized Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline to Final Assessment | All Enrolled Participants | 14.6 | Standard Deviation 0.0 | mL/min/1.73m^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05208866/results